Adeno-associated virus (AAV) is a non-enveloped DNA virus infecting a wide variety of species, tissues and cell types, which is recognized as safe and effective method for delivering therapeutic transgenes. AAV vector is the most popular viral gene delivery system in clinical delivery system with unique and multiple advantages, such as tissue tropism, transduction specificity, long-lasting gene expression, low immune responses, without host chromosome incorporation. Till now, four AAV-based gene therapy drugs have already been approved by the US Food and Drug Administration (FDA) or European Medicines Agency (EMA). In this study, we address the different approaches to optimize AAV vector delivery system with focus on capsid engineering, packaging capacity, immune response at the clinical level. The sstudy further investigates the potential of manipulating AAV vectors in preclinical applications and clinical translation, which emphasizes the challenges and prospects in viral vector selection, drug delivery strategies, immune reactions in cancer immunotherapy. Finally, it forecasts future directions and potential challenges of artificial intelligence (AI), vaccine, and nanobody, which emphasizes the need for ethical and secure approaches in AAV application.

Author registration and submission: https://accscience.com/user/login. Submit your paper along with a cover letter, including the special issue title. Your paper will undergo a fair peer review and be published immediately after acceptance and will be available to an international audience.